{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:24:39Z","timestamp":1787019879856,"version":"build-2736575974"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T00:00:00Z","timestamp":1343088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/2046-4053-1-33","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T12:14:48Z","timestamp":1343132088000},"source":"Crossref","is-referenced-by-count":120,"title":["Treatment of hyperprolactinemia: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"1","author":[{"given":"Amy T","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Hazem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaithra","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola W","family":"Gathaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Merc\u00e8","family":"Fern\u00e1ndez-Balsells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bagatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Coto-Yglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantey","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarig A","family":"Elraiyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J","family":"Erwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan Y","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M","family":"Montori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,24]]},"reference":[{"key":"31_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol. 2006, 65: 265-273. 10.1111\/j.1365-2265.2006.02562.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"M Gillam","year":"2006","unstructured":"Gillam M, Molitch M, Lombardi G, Colao A: Advances in the treatment of prolactinomas. Endocr Rev. 2006, 27: 485-534. 10.1210\/er.2005-9998.","journal-title":"Endocr Rev"},{"key":"31_CR3","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009, 339: b2535-10.1136\/bmj.b2535.","journal-title":"BMJ"},{"key":"31_CR4","unstructured":"Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. , http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm ,"},{"key":"31_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1210\/jc.2007-1907","volume":"93","author":"BA Swiglo","year":"2008","unstructured":"Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008, 93: 666-673.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"31_CR7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327: 557-560. 10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"31_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S0015-0282(98)00164-2","volume":"70","author":"F Hirahara","year":"1998","unstructured":"Hirahara F, Andoh N, Sawai K, Hirabuki T, Uemura T, Minaguchi H: Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril. 1998, 70: 246-252. 10.1016\/S0015-0282(98)00164-2.","journal-title":"Fertil Steril"},{"key":"31_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","volume":"32","author":"R Homburg","year":"1990","unstructured":"Homburg R, West C, Brownell J, Jacobs HS: A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol. 1990, 32: 565-571. 10.1111\/j.1365-2265.1990.tb00899.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0015-0282(16)55201-7","volume":"58","author":"RE Lappohn","year":"1992","unstructured":"Lappohn RE, van de Wiel HB, Brownell J: The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia. Fertil Steril. 1992, 58: 321-327.","journal-title":"Fertil Steril"},{"key":"31_CR11","first-page":"753","volume":"24","author":"V Pascal-Vigneron","year":"1995","unstructured":"Pascal-Vigneron V, Weryha G, Bosc M, Leclere J: Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med. 1995, 24: 753-757.","journal-title":"Presse Med"},{"key":"31_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","volume":"40","author":"PF van der Heijden","year":"1991","unstructured":"van der Heijden PF, de Wit W, Brownell J, Schoemaker J, Rolland R: CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol. 1991, 40: 111-118. 10.1016\/0028-2243(91)90101-P.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"31_CR13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1530\/acta.0.1250385","volume":"125","author":"JA Verhelst","year":"1991","unstructured":"Verhelst JA, Froud AL, Touzel R, Wass JA, Besser GM, Grossman AB: Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study. Acta Endocrinol. 1991, 125: 385-391.","journal-title":"Acta Endocrinol"},{"key":"31_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari C, Ismail I, Scanlon M: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994, 331: 904-909. 10.1056\/NEJM199410063311403.","journal-title":"N Engl J Med"},{"key":"31_CR15","first-page":"670","volume":"131","author":"S Motazedian","year":"2010","unstructured":"Motazedian S, Babakhani L, Fereshtehnejad SM, Mojtahedi K: A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. Indian J Med Res. 2010, 131: 670-674.","journal-title":"Indian J Med Res"},{"key":"31_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3109\/09513591003632233","volume":"26","author":"M Bahceci","year":"2010","unstructured":"Bahceci M, Sismanoglu A, Ulug U: Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol Endocrinol. 2010, 26: 505-508. 10.3109\/09513591003632233.","journal-title":"Gynecol Endocrinol"},{"key":"31_CR17","first-page":"286","volume":"138","author":"M De Rosa","year":"1998","unstructured":"De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, Paesano L, Merola B, Lombardi G: Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur. 1998, 138: 286-293.","journal-title":"Eur"},{"key":"31_CR18","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/mds.20201","volume":"19","author":"J Horvath","year":"2004","unstructured":"Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004, 19: 656-662. 10.1002\/mds.20201.","journal-title":"Mov Disord"},{"key":"31_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/mds.20202","volume":"19","author":"O Rascol","year":"2004","unstructured":"Rascol O, Pathak A, Bagheri H, Montastruc JL: New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord. 2004, 19: 611-613. 10.1002\/mds.20202.","journal-title":"Mov Disord"},{"key":"31_CR20","first-page":"667","volume":"162","author":"M Lafeber","year":"2010","unstructured":"Lafeber M, Stades AME, Valk GD, Cramer MJ, van Berkhout FT, Zelissen PMJ: Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur. 2010, 162: 667-675.","journal-title":"Eur"},{"key":"31_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2265.2010.03827.x","volume":"73","author":"T Tan","year":"2010","unstructured":"Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P, Martin NM: Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol. 2010, 73: 369-374. 10.1111\/j.1365-2265.2010.03827.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1210\/jc.2009-2095","volume":"95","author":"E Valassi","year":"2010","unstructured":"Valassi E, Klibanski A, Biller BM: Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010, 95: 1025-1033. 10.1210\/jc.2009-2095.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/bmj.39070.527986.68","volume":"334","author":"P Glasziou","year":"2007","unstructured":"Glasziou P, Chalmers I, Rawlins M, McCulloch P: When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007, 334: 349-351. 10.1136\/bmj.39070.527986.68.","journal-title":"BMJ"},{"key":"31_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M: Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol. 2008, 158: 11-18. 10.1530\/EJE-07-0248.","journal-title":"Eur J Endocrinol"},{"key":"31_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA: Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96: 273-288. 10.1210\/jc.2010-1692.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"O Dekkers","year":"2010","unstructured":"Dekkers O, Lagro J, Burman P, J\u00f8rgensen J, Romijn J, Pereira A: Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab. 2010, 95: 43-51. 10.1210\/jc.2009-1238.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11102-010-0290-z","volume":"14","author":"V Dos Santos Nunes","year":"2011","unstructured":"Dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR: Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary. 2011, 14: 259-265. 10.1007\/s11102-010-0290-z.","journal-title":"Pituitary"},{"key":"31_CR28","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.299.21.2543","volume":"299","author":"GY Gandhi","year":"2008","unstructured":"Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, Swiglo BA, Isley WL, Guyatt GH, Montori VM: Patient-important outcomes in registered diabetes trials. JAMA. 2008, 299: 2543-2549. 10.1001\/jama.299.21.2543.","journal-title":"JAMA"},{"key":"31_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s007010170075","volume":"143","author":"S Asano","year":"2001","unstructured":"Asano S, Ueki K, Suzuki I, Kirino T: Clinical features and medical treatment of male prolactinomas. Acta Neurochir. 2001, 143: 465-470. 10.1007\/s007010170075.","journal-title":"Acta Neurochir"},{"key":"31_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000182496","volume":"38","author":"T Brue","year":"1992","unstructured":"Brue T, Pellegrini I, Priou A, Morange I, Jaquet P: Prolactinomas and resistance to dopamine agonists. Horm Res. 1992, 38: 84-89. 10.1159\/000182496.","journal-title":"Horm Res"},{"key":"31_CR31","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1227\/00006123-198712000-00018","volume":"21","author":"R Candrina","year":"1987","unstructured":"Candrina R, Galli G, Bollati A, Pizzocolo G, Orlandini A, Gualandi GF, Giustina G: Results of combined surgical and medical therapy in patients with prolactin-secreting pituitary macroadenomas. Neurosurgery. 1987, 21: 894-897. 10.1227\/00006123-198712000-00018.","journal-title":"Neurosurgery"},{"key":"31_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000184630","volume":"44","author":"A Colao","year":"1995","unstructured":"Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G: Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Horm Res. 1995, 44: 222-228. 10.1159\/000184630.","journal-title":"Horm Res"},{"key":"31_CR33","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A: Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001, 86: 5256-5261. 10.1210\/jc.86.11.5256.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","volume":"83","author":"C Di Somma","year":"1998","unstructured":"Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G: Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab. 1998, 83: 807-813. 10.1210\/jc.83.3.807.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR35","first-page":"123","volume":"53","author":"G Hildebrandt","year":"1992","unstructured":"Hildebrandt G, Bauer T, Stracke H, Fassbender WJ, Mueller HW, Agnoli AL, Federlin K, Roosen K: Surgery, dopamine agonist therapy of combined treatment\u2013results in prolactinoma patients after a 12 month follow-up. Zentralbl Neurochir. 1992, 53: 123-134.","journal-title":"Zentralbl Neurochir"},{"key":"31_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","volume":"45","author":"WJ Jeffcoate","year":"1996","unstructured":"Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J: Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 1996, 45: 299-303. 10.1046\/j.1365-2265.1996.00824.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"31_CR37","first-page":"255","volume":"26","author":"IH Mahmood","year":"2010","unstructured":"Mahmood IH, Al-Husaynei AJ, Mohamad SH: Comparative effects of bromocriptine and cabergoline on serum prolactin levels, liver and kidney function tests in hyperprolactinemic women. Pak J Med Sci. 2010, 26: 255-260.","journal-title":"Pak J Med Sci"},{"key":"31_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1749-6632.1991.tb37907.x","volume":"626","author":"AM Mattei","year":"1991","unstructured":"Mattei AM, Severini V, Crosignani PG: Natural history of hyperprolactinemia. Ann N Y Acad Sci. 1991, 626: 130-136. 10.1111\/j.1749-6632.1991.tb37907.x.","journal-title":"Ann N Y Acad Sci"},{"key":"31_CR39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0344-0338(11)80151-2","volume":"187","author":"G Perrin","year":"1991","unstructured":"Perrin G, Treluyer C, Trouillas J, Sassolas G, Goutelle A: Surgical outcome and pathological effects of bromocriptine preoperative treatment in prolactinomas. Pathol Res Pract. 1991, 187: 587-592. 10.1016\/S0344-0338(11)80151-2.","journal-title":"Pathol Res Pract"},{"key":"31_CR40","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1210\/jc.85.9.3053","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A: Primary medical therapy of micro- and macroprolactinomas in men.[see comment]. J Clin Endocrinol Metab. 2000, 85: 3053-3057. 10.1210\/jc.85.9.3053.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1227\/00006123-199104000-00003","volume":"28","author":"S Rush","year":"1991","unstructured":"Rush S, Donahue B, Cooper P, Lee C, Persky M, Newall J: Prolactin reduction after combined therapy for prolactin macroadenomas. Neurosurgery. 1991, 28: 502-505. 10.1227\/00006123-199104000-00003.","journal-title":"Neurosurgery"},{"key":"31_CR42","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/0002-9378(86)90164-X","volume":"155","author":"NA Samaan","year":"1986","unstructured":"Samaan NA, Schultz PN, Leavens TA, Leavens ME, Lee YY: Pregnancy after treatment in patients with prolactinoma: operation versus bromocriptine. Am J Obstet Gynecol. 1986, 155: 1300-1305.","journal-title":"Am J Obstet Gynecol"},{"key":"31_CR43","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/BF03350694","volume":"13","author":"A Sartorio","year":"1990","unstructured":"Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G: Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest. 1990, 13: 419-422.","journal-title":"J Endocrinol Invest"},{"key":"31_CR44","first-page":"38","volume":"6","author":"CJ Shih","year":"1983","unstructured":"Shih CJ, Tsou CK, Chiu WT, Tsai SH: Management of prolactin-secreting pituitary adenomas with surgery and bromocriptine. Southeast Asian J Surg. 1983, 6: 38-46.","journal-title":"Southeast Asian J Surg"},{"key":"31_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0015-0282(16)55139-5","volume":"58","author":"AV Sluijmer","year":"1992","unstructured":"Sluijmer AV, Lappohn RE: Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril. 1992, 58: 72-77.","journal-title":"Fertil Steril"},{"key":"31_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ten.0000240933.97458.bf","volume":"16","author":"I Torres","year":"2006","unstructured":"Torres I, Carral F, Vilchez F, Gavil\u00e1n J, Aguilar M: Clinical, radiologic, and follow-up findings in patients with macroprolactinoma. Endocrinologist. 2006, 16: 241-244. 10.1097\/01.ten.0000240933.97458.bf.","journal-title":"Endocrinologist"},{"key":"31_CR47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1034\/j.1600-0412.2001.080002162.x","volume":"80","author":"P Touraine","year":"2001","unstructured":"Touraine P, Plu-Bureau G, Beji C, Mauvais-Jarvis P, Kuttenn F: Long-term follow-up of 246 hyperprolactinemic patients. Acta Obstet Gynecol Scand. 2001, 80: 162-168. 10.1034\/j.1600-0412.2001.080002162.x.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"31_CR48","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994, 331: 904-909. 10.1056\/NEJM199410063311403.","journal-title":"N Engl J Med"},{"key":"31_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","volume":"63","author":"M Biswas","year":"2005","unstructured":"Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS: Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol. 2005, 63: 26-31. 10.1111\/j.1365-2265.2005.02293.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF03343573","volume":"22","author":"S Cannavo","year":"1999","unstructured":"Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F: Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest. 1999, 22: 354-359.","journal-title":"J Endocrinol Invest"},{"key":"31_CR51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/BF03348017","volume":"20","author":"E Ciccarelli","year":"1997","unstructured":"Ciccarelli E, Grottoli S, Razzore P, Gaia D, Bertagna A, Cirillo S, Cammarota T, Camanni M, Camanni F: Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest. 1997, 20: 547-551.","journal-title":"J Endocrinol Invest"},{"key":"31_CR52","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G: Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.[see comment]. N Engl J Med. 2003, 349: 2023-2033. 10.1056\/NEJMoa022657.","journal-title":"N Engl J Med"},{"key":"31_CR53","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0015-0282(16)59790-8","volume":"49","author":"B Corenblum","year":"1988","unstructured":"Corenblum B, Taylor PJ: Idiopathic hyperprolactinemia may include a distinct entity with a natural history different from that of prolactin adenomas. Fertil Steril. 1988, 49: 544-546.","journal-title":"Fertil Steril"},{"key":"31_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A: The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf). 2000, 53: 53-60. 10.1046\/j.1365-2265.2000.01016.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"31_CR55","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/acta.0.0920413","volume":"92","author":"T Eversmann","year":"1979","unstructured":"Eversmann T, Fahlbusch R, Rjosk HK, von Werder K: Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Acta Endocrinol (Copenh). 1979, 92: 413-427.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/bmj.290.6462.117-a","volume":"290","author":"KW Hancock","year":"1985","unstructured":"Hancock KW, Scott JS, Lamb JT, Gibson RM, Chapman C: Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas. Br Med J (Clin Res Ed). 1985, 290: 117-118.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"31_CR57","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/0002-9343(83)90418-7","volume":"75","author":"DG Johnston","year":"1983","unstructured":"Johnston DG, Prescott RW, Kendall-Taylor P, Hall K, Crombie AL, Hall R, McGregor A, Watson MJ, Cook DB: Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med. 1983, 75: 868-874. 10.1016\/0002-9343(83)90418-7.","journal-title":"Am J Med"},{"key":"31_CR58","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip J, Salvatori R, Yenokyan G, Wand GS: Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.[see comment]. J Clin Endocrinol Metab. 2009, 94: 2428-2436. 10.1210\/jc.2008-2103.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR59","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJM198509123131103","volume":"313","author":"A Liuzzi","year":"1985","unstructured":"Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G: Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med. 1985, 313: 656-659. 10.1056\/NEJM198509123131103.","journal-title":"N Engl J Med"},{"key":"31_CR60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1471-0528.1984.tb04761.x","volume":"91","author":"AM Mattei","year":"1984","unstructured":"Mattei AM, Ferrari C, Ragni G, Benco R, Picciotti MC, Rampini P, Caldara R, Crosignani PG: Serum prolactin and ovarian function after discontinuation of drug treatment for hyperprolactinaemia: a study with bromocriptine and metergoline. Br J Obstet Gynaecol. 1984, 91: 244-250. 10.1111\/j.1471-0528.1984.tb04761.x.","journal-title":"Br J Obstet Gynaecol"},{"key":"31_CR61","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1210\/jcem-60-4-764","volume":"60","author":"P Moriondo","year":"1985","unstructured":"Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G: Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab. 1985, 60: 764-772. 10.1210\/jcem-60-4-764.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR62","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/BF03348016","volume":"20","author":"M Muratori","year":"1997","unstructured":"Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G: Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest. 1997, 20: 537-546.","journal-title":"J Endocrinol Invest"},{"key":"31_CR63","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","volume":"87","author":"VQ Passos","year":"2002","unstructured":"Passos VQ, Souza JJ, Musolino NR, Bronstein MD: Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab. 2002, 87: 3578-3582. 10.1210\/jc.87.8.3578.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR64","first-page":"301","volume":"22","author":"M Tartagni","year":"1995","unstructured":"Tartagni M, Nicastri PL, Diaferia A, Di Gesu I, Loizzi P: Long-term follow-up of women with amenorrhea-galactorrhea treated with bromocriptine. Clin Exp Obstet Gynecol. 1995, 22: 301-306.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"31_CR65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","volume":"34","author":"JW van 't Verlaat","year":"1991","unstructured":"van 't Verlaat JW, Croughs RJ: Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.[see comment]. Clin Endocrinol (Oxf). 1991, 34: 175-178. 10.1111\/j.1365-2265.1991.tb00289.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"31_CR66","first-page":"817","volume-title":"Basic and Clinical Correlates","author":"W Winkelmann","year":"1985","unstructured":"Winkelmann W, Allolio B, Deuss U, Heesen D, Kaulen D: Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. Basic and Clinical Correlates. Edited by: Macleod RM, Thorner MO, Scapagnini U. 1985, Liviana Press, Padova, 817-822."},{"key":"31_CR67","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3171\/jns.2006.104.1.54","volume":"104","author":"ZB Wu","year":"2006","unstructured":"Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS, Zheng WM: Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg. 2006, 104: 54-61. 10.3171\/jns.2006.104.1.54.","journal-title":"J Neurosurg"},{"key":"31_CR68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/acta.0.1040139","volume":"104","author":"A Zarate","year":"1983","unstructured":"Zarate A, Canales ES, Cano C, Pilonieta CJ: Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh). 1983, 104: 139-142.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1479-828X.1989.tb01712.x","volume":"29","author":"SA Al-Suleiman","year":"1989","unstructured":"Al-Suleiman SA, Najashi S, Rahman J, Rahman MS: Outcome of treatment with bromocriptine in patients with hyperprolactinaemia. Aust N Z J Obstet Gynaecol. 1989, 29: 176-179. 10.1111\/j.1479-828X.1989.tb01712.x.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"31_CR70","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1530\/acta.0.0880435","volume":"88","author":"T Bergh","year":"1978","unstructured":"Bergh T, Nillius J, Wide L: Bromocriptine treatment of 42 hyperprolactinaemic women with secondary amenorrhoea. Acta Endocrinol (Copenh). 1978, 88: 435-451.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR71","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0015-0282(16)54779-7","volume":"57","author":"T Brue","year":"1992","unstructured":"Brue T, Lancranjan I, Louvet JP, Dewailly D, Roger P, Jaquet P: A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study. Fertil Steril. 1992, 57: 74-80.","journal-title":"Fertil Steril"},{"key":"31_CR72","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-2265.1992.tb02300.x","volume":"37","author":"S Cannavo","year":"1992","unstructured":"Cannavo S, De Natale R, Curto L, Li Calzi L, Trimarchi F: Effectiveness of computer-assisted perimetry in the follow-up of patients with pituitary microadenoma responsive to medical treatment. Clin Endocrinol. 1992, 37: 157-161. 10.1111\/j.1365-2265.1992.tb02300.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11102-005-5111-4","volume":"8","author":"A Chattopadhyay","year":"2005","unstructured":"Chattopadhyay A, Bhansali A, Masoodi SR: Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary. 2005, 8: 147-154. 10.1007\/s11102-005-5111-4.","journal-title":"Pituitary"},{"key":"31_CR74","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0015-0282(16)47415-7","volume":"40","author":"B Corenblum","year":"1983","unstructured":"Corenblum B, Taylor PJ: Long-term follow-up of hyperprolactinemic women treated with bromocriptine. Fertil Steril. 1983, 40: 596-599.","journal-title":"Fertil Steril"},{"key":"31_CR75","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0015-0282(16)57052-6","volume":"62","author":"JJ Espinos","year":"1994","unstructured":"Espinos JJ, Rodriguez-Espinosa J, Webb SM, Calaf-Alsina J: Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics. Fertil Steril. 1994, 62: 926-931.","journal-title":"Fertil Steril"},{"key":"31_CR76","first-page":"524","volume":"63","author":"O Essais","year":"2002","unstructured":"Essais O, Bouguerra R, Hamzaoui J, Marrakchi Z, Hadjri S, Chamakhi S, Zidi B, Ben Slama C: Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol. 2002, 63: 524-531.","journal-title":"Ann Endocrinol"},{"key":"31_CR77","first-page":"1063","volume":"43","author":"L Falsetti","year":"1988","unstructured":"Falsetti L, Zanagnolo V, Gastaldi A: A retrospective study of idiopathic hyperprolactinemias. Curr Ther Res Clin Exp. 1988, 43: 1063-1072.","journal-title":"Curr Ther Res Clin Exp"},{"key":"31_CR78","first-page":"283","volume":"59","author":"VM Fletes Rabago","year":"1991","unstructured":"Fletes Rabago VM, Torres Farias S, Dominguez Jimenez A, Padilla Ruiz R: [Alternative to bromocriptine (BEC) management in patients with prolactinoma and intolerance to oral BEC]. Ginecol Obstet Mex. 1991, 59: 283-288.","journal-title":"Ginecol Obstet Mex"},{"key":"31_CR79","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-110-7-526","volume":"110","author":"SL Greenspan","year":"1989","unstructured":"Greenspan SL, Oppenheim DS, Klibanski A: Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1989, 110: 526-531.","journal-title":"Ann Intern Med"},{"key":"31_CR80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2265.1993.tb00989.x","volume":"38","author":"R Haase","year":"1993","unstructured":"Haase R, Jaspers C, Schulte HM, Lancranja I, Pfingsten H, Orri-Fend M, Reinwein D, Benker G: Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years. Clin Endocrinol. 1993, 38: 165-176. 10.1111\/j.1365-2265.1993.tb00989.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000216502","volume":"11","author":"W Holtkamp","year":"1988","unstructured":"Holtkamp W, Nagel GA: Bromocriptine with chemotherapy resistant, metastatic breast cancer. Results of the AIO-Study GO-MC-BROMO 2\/82. Onkologie. 1988, 11: 121-127. 10.1159\/000216502.","journal-title":"Onkologie"},{"key":"31_CR82","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/BF03349893","volume":"19","author":"SI Jamrozik","year":"1996","unstructured":"Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP: Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients. J Endocrinol Invest. 1996, 19: 472-479.","journal-title":"J Endocrinol Invest"},{"key":"31_CR83","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/S0015-0282(16)55914-7","volume":"59","author":"AM Lengyel","year":"1993","unstructured":"Lengyel AM, Mussio W, Imamura P, Vieira JG, Lancranjan I: Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas. Fertil Steril. 1993, 59: 980-987.","journal-title":"Fertil Steril"},{"key":"31_CR84","first-page":"28","volume":"27","author":"SQ Lin","year":"1992","unstructured":"Lin SQ: Experiences with bromocriptine treatment of female infertility due to hyperprolactinemia. Zhonghua Fu Chan Ke Za Zhi. 1992, 27: 28-31.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"31_CR85","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1227\/00006123-199108000-00005","volume":"29","author":"E Moberg","year":"1991","unstructured":"Moberg E, af Trampe E, Wersall J, Werner S: Long-term effects of radiotherapy and bromocriptine treatment in patients with previous surgery for macroprolactinomas. Neurosurgery. 1991, 29: 200-204. 10.1227\/00006123-199108000-00005. discussion 204-205","journal-title":"Neurosurgery"},{"key":"31_CR86","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1530\/acta.0.1250494","volume":"125","author":"C Maraschini","year":"1991","unstructured":"Maraschini C, Moro M, Masala A, Toja P, Alagna S, Brunani A, Rovasio PP, Ginanni A, Lancranjan I, Cavagnini F: Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol (Copenh). 1991, 125: 494-501.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR87","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF03348700","volume":"15","author":"B Merola","year":"1992","unstructured":"Merola B, Colao A, Caruso E, Sarnacchiaro F, Lancranjan I, Lombardi G, Schettini G: Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia. J Endocrinol Invest. 1992, 15: 173-176.","journal-title":"J Endocrinol Invest"},{"key":"31_CR88","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985, 60: 698-705. 10.1210\/jcem-60-4-698.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR89","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1210\/jcem-47-2-290","volume":"47","author":"R Mornex","year":"1978","unstructured":"Mornex R, Orgiazzi J, Hugues B, Gagnaire JC, Claustrat B: Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors. J Clin Endocrinol Metab. 1978, 47: 290-295. 10.1210\/jcem-47-2-290.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR90","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000181889","volume":"35","author":"M Moro","year":"1991","unstructured":"Moro M, Maraschini C, Toja P, Masala A, Alagna S, Rovasio PP, Ginanni A, Lancranjan I, Cavagnini F: Comparison between a slow-release oral preparation of bromocriptine and regular bromocriptine in patients with hyperprolactinemia: a double blind, double dummy study. Horm Res. 1991, 35: 137-141. 10.1159\/000181889.","journal-title":"Horm Res"},{"key":"31_CR91","first-page":"124","volume":"21","author":"AM Paoletti","year":"1994","unstructured":"Paoletti AM, Cagnacci A, Mais V, Ajossa S, Guerriero S, Murgia C, Depau GF, Serra GG, Melis GB: Shrinkage of pituitary PRL-secernent adenoma after short-term treatment with bromocriptine long-acting repeatable injections. Clin Exp Obstet Gynecol. 1994, 21: 124-128.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"31_CR92","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1479-828X.1990.tb03228.x","volume":"30","author":"C Rasmussen","year":"1990","unstructured":"Rasmussen C, Larsson SG, Bergh T: Long-term radiographic follow-up of the sella turcica in hyperprolactinaemic women. Aust N Z J Obstet Gynaecol. 1990, 30: 257-264. 10.1111\/j.1479-828X.1990.tb03228.x.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"31_CR93","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-2265.1990.tb00479.x","volume":"33","author":"G Schettini","year":"1990","unstructured":"Schettini G, Lombardi G, Merola B, Colao A, Miletto P, Caruso E, Lancranjan I: Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol. 1990, 33: 161-169. 10.1111\/j.1365-2265.1990.tb00479.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR94","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/BF02939147","volume":"149","author":"P Skrabanek","year":"1980","unstructured":"Skrabanek P, McDonald D, De Valera E: Plasma prolactin in amenorrhoea, infertility, and other disorders: A retrospective study of 608 patients. Ir J Med Sci. 1980, 149: 236-245. 10.1007\/BF02939147.","journal-title":"Ir J Med Sci"},{"key":"31_CR95","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1001\/jama.1982.03320280031025","volume":"247","author":"RF Spark","year":"1982","unstructured":"Spark RF, Baker R, Bienfang DC, Bergland R: Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery?. JAMA. 1982, 247: 311-316. 10.1001\/jama.1982.03320280031025.","journal-title":"JAMA"},{"key":"31_CR96","first-page":"131","volume":"216","author":"MO Thorner","year":"1978","unstructured":"Thorner MO, Besser GM: Bromocriptine treatment of hyperprolactinaemic hypogonadism. Acta Endocrinol Suppl. 1978, 216: 131-146.","journal-title":"Acta Endocrinol Suppl"},{"key":"31_CR97","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2265.1995.tb02685.x","volume":"42","author":"S Tsagarakis","year":"1995","unstructured":"Tsagarakis S, Tsiganou E, Tzavara I, Nikolou H, Thalassinos N: Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas. Clin Endocrinol. 1995, 42: 593-599. 10.1111\/j.1365-2265.1995.tb02685.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR98","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1530\/acta.0.1120487","volume":"112","author":"JW van 't Verlaat","year":"1986","unstructured":"van 't Verlaat JW, Croughs RJ, Hendriks MJ, Bosma NJ, Nortier JW, Thijssen JH: Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study. Acta Endocrinol (Copenh). 1986, 112: 487-493.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR99","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1445-5994.1997.tb02196.x","volume":"27","author":"JP Walsh","year":"1997","unstructured":"Walsh JP, Pullan PT: Hyperprolactinaemia in males: a heterogeneous disorder. Aust N Z J Med. 1997, 27: 385-390. 10.1111\/j.1445-5994.1997.tb02196.x.","journal-title":"Aust N Z J Med"},{"key":"31_CR100","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1136\/bmj.284.6333.1908","volume":"284","author":"JA Wass","year":"1982","unstructured":"Wass JA, Williams J, Charlesworth M, Kingsley DP, Halliday AM, Doniach I, Rees LH, McDonald WI, Besser GM: Bromocriptine in management of large pituitary tumours. Br Med J (Clin Res Ed). 1982, 284: 1908-1911. 10.1136\/bmj.284.6333.1908.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"31_CR101","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0015-0282(16)54840-7","volume":"57","author":"CO Weingrill","year":"1992","unstructured":"Weingrill CO, Mussio W, Moraes CR, Portes E, Castro RC, Lengyel AM: Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia. Fertil Steril. 1992, 57: 331-335.","journal-title":"Fertil Steril"},{"key":"31_CR102","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11060-010-0459-3","volume":"104","author":"MS Yang","year":"2011","unstructured":"Yang MS, Hong JW, Lee SK, Lee EJ, Kim SH: Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. J Neurooncol. 2011, 104: 195-204. 10.1007\/s11060-010-0459-3.","journal-title":"J Neurooncol"},{"key":"31_CR103","first-page":"530","volume":"131","author":"A Bhansali","year":"2010","unstructured":"Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S: Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. Indian J Med Res. 2010, 131: 530-535.","journal-title":"Indian J Med Res"},{"key":"31_CR104","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1210\/jc.81.6.2338","volume":"81","author":"BMK Biller","year":"1996","unstructured":"Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996, 81: 2338-2343. 10.1210\/jc.81.6.2338.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR105","first-page":"489","volume":"109","author":"P Bolko","year":"2003","unstructured":"Bolko P, Jaskula M, Wasko R, Wolun M, Sowinski J: The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type. Polskie Archiwum Medycyny Wewnetrznej. 2003, 109: 489-495.","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"31_CR106","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00404-010-1562-6","volume":"282","author":"EE Buyukbayrak","year":"2010","unstructured":"Buyukbayrak EE, Karageyim Karsidag AY, Kars B, Balcik O, Pirimoglu M, Unal O, Turan C: Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. Arch Gynecol Obstet. 2010, 282: 561-566. 10.1007\/s00404-010-1562-6.","journal-title":"Arch Gynecol Obstet"},{"key":"31_CR107","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3346\/jkms.2009.24.5.874","volume":"24","author":"E-H Cho","year":"2009","unstructured":"Cho E-H, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim M-S: Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci. 2009, 24: 874-878. 10.3346\/jkms.2009.24.5.874.","journal-title":"J Korean Med Sci"},{"key":"31_CR108","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1210\/jcem-69-4-725","volume":"69","author":"E Ciccarelli","year":"1989","unstructured":"Ciccarelli E, Giusti M, Miola C, Potenzoni F, Sghedoni D, Camanni F, Giordano G: Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab. 1989, 69: 725-728. 10.1210\/jcem-69-4-725.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR109","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997, 82: 3574-3579. 10.1210\/jc.82.11.3574.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR110","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1210\/jc.85.6.2247","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000, 85: 2247-2252. 10.1210\/jc.85.6.2247.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR111","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2003-032055","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A, Lombardi G: Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab. 2004, 89: 2770-2775. 10.1210\/jc.2003-032055.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR112","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G: Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004, 89: 1704-1711. 10.1210\/jc.2003-030979.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR113","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1046\/j.1365-2265.2003.01770.x","volume":"58","author":"SM Corsello","year":"2003","unstructured":"Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C: Giant prolactinomas in men: Efficacy of cabergoline treatment. Clin Endocrinol. 2003, 58: 662-670. 10.1046\/j.1365-2265.2003.01770.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR114","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1365-2265.2008.03200.x","volume":"69","author":"A De Bellis","year":"2008","unstructured":"De Bellis A, Colao A, Savoia A, Coronella C, Pasquali D, Conte M, Pivonello R, Bellastella A, Sinisi AA, Bizzarro A, Lombardi G, Bellastella G: Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies. Clin Endocrinol. 2008, 69: 285-291. 10.1111\/j.1365-2265.2008.03200.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR115","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","volume":"64","author":"M De Rosa","year":"2006","unstructured":"De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, Lombardi G, Colao A: The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol. 2006, 64: 307-313. 10.1111\/j.1365-2265.2006.02461.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR116","first-page":"454","volume":"134","author":"E Delgrange","year":"1996","unstructured":"Delgrange E, Maiter D, Donckier J: Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur. 1996, 134: 454-456.","journal-title":"Eur"},{"key":"31_CR117","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/acta.0.1260489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C, Paracchi A, Mattei AM, De Vincentiis S, D'Alberton A, Crosignani P: Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh). 1992, 126: 489-494.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR118","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","volume":"46","author":"CI Ferrari","year":"1997","unstructured":"Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol. 1997, 46: 409-413. 10.1046\/j.1365-2265.1997.1300952.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR119","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K: Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.[see comment]. J Clin Endocrinol Metab. 2008, 93: 4721-4727. 10.1210\/jc.2007-2758.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR120","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1210\/jc.2009-2605","volume":"95","author":"M Ono","year":"2010","unstructured":"Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S-, Okada Y, Hori T: Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab. 2010, 95: 2672-2679. 10.1210\/jc.2009-2605.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR121","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1023\/A:1009913200542","volume":"2","author":"N Pontikides","year":"2000","unstructured":"Pontikides N, Krassas GE, Nikopoulou E, Kaltsas T: Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary. 2000, 2: 277-281. 10.1023\/A:1009913200542.","journal-title":"Pituitary"},{"key":"31_CR122","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2265.2008.03364.x","volume":"70","author":"G Raverot","year":"2009","unstructured":"Raverot G, Jacob M, Jouanneau E, Delemer B, Vighetto A, Pugeat M, Borson-Chazot F: Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol. 2009, 70: 588-592. 10.1111\/j.1365-2265.2008.03364.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR123","first-page":"225","volume":"156","author":"I Shimon","year":"2007","unstructured":"Shimon I, Benbassat C, Hadani M: Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur. 2007, 156: 225-231.","journal-title":"Eur"},{"key":"31_CR124","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4103\/0028-3886.84332","volume":"59","author":"S Sinha","year":"2011","unstructured":"Sinha S, Sharma BS, Mahapatra AK: Microsurgical management of prolactinomas - clinical and hormonal outcome in a series of 172 cases. Neurol India. 2011, 59: 532-536. 10.4103\/0028-3886.84332.","journal-title":"Neurol India"},{"key":"31_CR125","first-page":"314","volume":"134","author":"R Walia","year":"2011","unstructured":"Walia R, Bhansali A, Dutta P, Khandelwal N, Sialy R, Bhadada S: Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline. Indian J Med Res. 2011, 134: 314-319.","journal-title":"Indian J Med Res"},{"key":"31_CR126","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","volume":"39","author":"J Webster","year":"1993","unstructured":"Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, L'Hermite M, Ciccarelli E: The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group. Clin Endocrinol. 1993, 39: 323-329. 10.1111\/j.1365-2265.1993.tb02372.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR127","first-page":"548","volume":"135","author":"A Colao","year":"1996","unstructured":"Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E, Zarrilli S, Merola B, Lombardi G: Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur. 1996, 135: 548-552.","journal-title":"Eur"},{"key":"31_CR128","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2265.1991.tb01731.x","volume":"34","author":"L Duranteau","year":"1991","unstructured":"Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM: Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol. 1991, 34: 25-29. 10.1111\/j.1365-2265.1991.tb01731.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/acta.0.1280301","volume":"128","author":"A Kvistborg","year":"1993","unstructured":"Kvistborg A, Halse J, Bakke S, Bjoro T, Hansen E, Djoseland O, Brownell J, Jervell J: Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol (Copenh). 1993, 128: 301-307.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR130","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0753-3322(94)90105-8","volume":"48","author":"B Merola","year":"1994","unstructured":"Merola B, Sarnacchiaro F, Colao A, Disomma C, Disarno A, Landi ML, Marzullo P, Panza N, Battista C, Lombardi G: CV-205-502 in the treatment of tumoral and nontumoral hyperprolactinemic states. Biomed Pharmacother. 1994, 48: 167-174. 10.1016\/0753-3322(94)90105-8.","journal-title":"Biomed Pharmacother"},{"key":"31_CR131","first-page":"413","volume":"135","author":"I Morange","year":"1996","unstructured":"Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P: Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy. Eur. 1996, 135: 413-420.","journal-title":"Eur"},{"key":"31_CR132","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2265.1989.tb01263.x","volume":"31","author":"CB Newman","year":"1989","unstructured":"Newman CB, Hurley AM, Kleinberg DL: Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol. 1989, 31: 391-400. 10.1111\/j.1365-2265.1989.tb01263.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR133","first-page":"421","volume":"43","author":"T Nickelsen","year":"1993","unstructured":"Nickelsen T, Jungmann E, Althoff P, Schummdraeger PM, Usadel KH: Treatment of macroprolactinoma with the new potent nonergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary-function, and the renin-aldosterone system- results of a clinical long-term study. Arzneimittelforschung. 1993, 43: 421-425.","journal-title":"Arzneimittelforschung"},{"key":"31_CR134","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2265.1988.tb01225.x","volume":"29","author":"C Rasmussen","year":"1988","unstructured":"Rasmussen C, Bergh T, Wide L, Brownell J: Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia. Clin Endocrinol. 1988, 29: 271-279. 10.1111\/j.1365-2265.1988.tb01225.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR135","first-page":"411","volume":"61","author":"V Rohmer","year":"2000","unstructured":"Rohmer V, Freneau E, Morange I, Simonetta C: Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Ann Endocrinol (Paris). 2000, 61: 411-417.","journal-title":"Ann Endocrinol (Paris)"},{"key":"31_CR136","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0015-0282(16)54175-2","volume":"55","author":"Z Shoham","year":"1991","unstructured":"Shoham Z, Homburg R, Jacobs HS: CV 205\u2013502\u2013effectiveness, tolerability, and safety over 24-month study. Fertil Steril. 1991, 55: 501-506.","journal-title":"Fertil Steril"},{"key":"31_CR137","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0015-0282(16)60966-4","volume":"52","author":"PF van der Heijden","year":"1989","unstructured":"van der Heijden PF, Lappohn RE, Corbey RS, de Goeij WB, Brownell J, Rolland R: The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study. Fertil Steril. 1989, 52: 574-579.","journal-title":"Fertil Steril"},{"key":"31_CR138","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1210\/jcem-72-5-1136","volume":"72","author":"AJ van der Lely","year":"1991","unstructured":"van der Lely AJ, Brownell J, Lamberts SW: The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab. 1991, 72: 1136-1141. 10.1210\/jcem-72-5-1136.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR139","doi-asserted-by":"publisher","first-page":"668","DOI":"10.7326\/0003-4819-112-9-668","volume":"112","author":"ML Vance","year":"1990","unstructured":"Vance ML, Lipper M, Klibanski A, Biller BMK, Samaan NA, Molitch ME: Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med. 1990, 112: 668-673.","journal-title":"Ann Intern Med"},{"key":"31_CR140","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/j.1365-2265.1994.tb02799.x","volume":"41","author":"L Vilar","year":"1994","unstructured":"Vilar L, Burke CW: Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.[see comment]. Clin Endocrinol. 1994, 41: 821-826. 10.1111\/j.1365-2265.1994.tb02799.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR141","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1210\/jcem.85.1.6329","volume":"85","author":"PU Freda","year":"2000","unstructured":"Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL: Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab. 2000, 85: 8-13. 10.1210\/jc.85.1.8.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR142","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/BF00180520","volume":"72","author":"C Jaspers","year":"1994","unstructured":"Jaspers C, Benker G, Reinwein D: Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: First results. Clin Investig. 1994, 72: 451-456.","journal-title":"Clin Investig"},{"key":"31_CR143","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1012836331506","volume":"3","author":"JJ Orrego","year":"2000","unstructured":"Orrego JJ, Chandler WF, Barkan AL: Pergolide as primary therapy for macroprolactinomas. Pituitary. 2000, 3: 251-256. 10.1023\/A:1012836331506.","journal-title":"Pituitary"},{"key":"31_CR144","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1023\/A:1025377816769","volume":"5","author":"L Sibal","year":"2002","unstructured":"Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH, Hall K, Quinton R: Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary. 2002, 5: 243-246. 10.1023\/A:1025377816769.","journal-title":"Pituitary"},{"key":"31_CR145","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/BF03349379","volume":"3","author":"G Verde","year":"1980","unstructured":"Verde G, Chiodini PG, Liuzzi A, Cozzi R, Favales F, Botalla L, Spelta B, Dalla Bonzana D, Rainer E, Horowski R: Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. J Endocrinol Invest. 1980, 3: 405-414.","journal-title":"J Endocrinol Invest"},{"key":"31_CR146","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1365-2265.2008.03384.x","volume":"70","author":"J Jezkova","year":"2009","unstructured":"Jezkova J, Hana V, Krsek M, Weiss V, Vladyka V, Liscak R, Vymazal J, Pecen L, Marek J: Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol. 2009, 70: 732-741. 10.1111\/j.1365-2265.2008.03384.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR147","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3171\/jns.2000.93.supplement_3.0010","volume":"93","author":"L Pan","year":"2000","unstructured":"Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW: Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg. 2000, 93: 10-13.","journal-title":"J Neurosurg"},{"key":"31_CR148","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1227\/01.NEU.0000223445.22938.BD","volume":"59","author":"N Pouratian","year":"2006","unstructured":"Pouratian N, Sheehan J, Jagannathan J, Laws ER, Steiner L, Vance ML: Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery. 2006, 59: 255-266. 10.1227\/01.NEU.0000223445.22938.BD. discussion 255-266","journal-title":"Neurosurgery"},{"key":"31_CR149","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10143-010-0285-2","volume":"34","author":"DQ Sun","year":"2010","unstructured":"Sun DQ, Cheng JJ, Frazier JL, Batra S, Wand G, Kleinberg LR, Rigamonti D, Quinones-Hinojosa A, Salvatori R, Lim M: Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev. 2010, 34: 181-189.","journal-title":"Neurosurg Rev"},{"key":"31_CR150","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2265.1991.tb00312.x","volume":"34","author":"S Tsagarakis","year":"1991","unstructured":"Tsagarakis S, Grossman A, Plowman PN, Jones AE, Touzel R, Rees LH, Wass JA, Besser GM: Megavoltage pituitary irradiation in the management of prolactinomas: long-term follow-up. Clin Endocrinol. 1991, 34: 399-406. 10.1111\/j.1365-2265.1991.tb00312.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR151","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0360-3016(98)00124-2","volume":"41","author":"SC Yoon","year":"1998","unstructured":"Yoon SC, Suh TS, Jang HS, Chung SM, Kim YS, Ryu MR, Choi KH, Son HY, Kim MC, Shinn KS: Clinical results of 24 pituitary macroadenomas with linac-based stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 1998, 41: 849-853. 10.1016\/S0360-3016(98)00124-2.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"31_CR152","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000048393","volume":"75","author":"N Zhang","year":"2000","unstructured":"Zhang N, Pan L, Dai J, Wang B, Wang E, Zhang W, Cai P: Gamma Knife radiosurgery as a primary surgical treatment for hypersecreting pituitary adenomas. Stereotact Funct Neurosurg. 2000, 75: 123-128. 10.1159\/000048393.","journal-title":"Stereotact Funct Neurosurg"},{"key":"31_CR153","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0360-3016(95)00071-6","volume":"33","author":"D Zierhut","year":"1995","unstructured":"Zierhut D, Flentje M, Adolph J, Erdmann J, Raue F, Wannenmacher M: External Radiotherapy of Pituitary Adenomas. Int J Radiat Oncol Biol Phys. 1995, 33: 307-314. 10.1016\/0360-3016(95)00071-6.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"31_CR154","first-page":"473","volume":"47","author":"WF Kelly","year":"1978","unstructured":"Kelly WF, Mashiter K, Doyle FH, Banks LM, Joplin GF: Treatment of prolactin-secreting pituitary tumours in young women by needle implantation of radioactive yttrium. Q J Med. 1978, 47: 473-493.","journal-title":"Q J Med"},{"key":"31_CR155","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/qjmed\/81.3.985","volume":"81","author":"MD Littley","year":"1991","unstructured":"Littley MD, Shalet SM, Reid H, Beardwell CG, Sutton ML: The effect of external pituitary irradiation on elevated serum prolactin levels in patients with pituitary macroadenomas. Q J Med. 1991, 81: 985-998. 10.1093\/qjmed\/81.3.985.","journal-title":"Q J Med"},{"key":"31_CR156","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/(SICI)1520-6823(1996)4:4<185::AID-ROI6>3.0.CO;2-U","volume":"4","author":"SB Rudoler","year":"1996","unstructured":"Rudoler SB, Ruffer JE, Gennarelli TA, Savino PJ, Fowble BF: Long-term results of radiotherapy for prolactin-secreting pituitary macroadenomas. Radiat Oncol Investig. 1996, 4: 185-191. 10.1002\/(SICI)1520-6823(1996)4:4<185::AID-ROI6>3.0.CO;2-U.","journal-title":"Radiat Oncol Investig"},{"key":"31_CR157","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.wneu.2010.05.007","volume":"74","author":"S Tanaka","year":"2010","unstructured":"Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF, Pollock BE: Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg. 2010, 74: 147-152. 10.1016\/j.wneu.2010.05.007.","journal-title":"World Neurosurg"},{"key":"31_CR158","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3171\/jns.2002.97.2.0307","volume":"97","author":"AP Amar","year":"2002","unstructured":"Amar AP, Couldwell WT, Chen JCT, Weiss MH: Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg. 2002, 97: 307-314. 10.3171\/jns.2002.97.2.0307.","journal-title":"J Neurosurg"},{"key":"31_CR159","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11102-010-0283-y","volume":"14","author":"M Babey","year":"2011","unstructured":"Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW: Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary. 2011, 14: 222-230. 10.1007\/s11102-010-0283-y.","journal-title":"Pituitary"},{"key":"31_CR160","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/0026-0495(82)90159-7","volume":"31","author":"A Barbarino","year":"1982","unstructured":"Barbarino A, De Marinis L, Anile C, Menini E, Merlini G, Maira G: Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery. Metabolism. 1982, 31: 1100-1104. 10.1016\/0026-0495(82)90159-7.","journal-title":"Metabolism"},{"key":"31_CR161","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000180098","volume":"22","author":"G Charpentier","year":"1985","unstructured":"Charpentier G, de Plunkett T, Jedynak P, Peillon F, Le Gentil P, Racadot J, Visot A, Derome P: Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors. Horm Res. 1985, 22: 222-227. 10.1159\/000180098.","journal-title":"Horm Res"},{"key":"31_CR162","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.surneu.2008.03.027","volume":"70","author":"JR Dusick","year":"2008","unstructured":"Dusick JR, Fatemi N, Mattozo C, McArthur D, Cohan P, Wang C, Swerdloff RS, Kelly DF: Pituitary function after endonasal surgery for nonadenomatous parasellar tumors: Rathke's cleft cysts, craniopharyngiomas, and meningiomas. Surg Neurol. 2008, 70: 482-490. 10.1016\/j.surneu.2008.03.027.","journal-title":"Surg Neurol"},{"key":"31_CR163","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1227\/01.NEU.0000325725.77132.90","volume":"63","author":"N Fatemi","year":"2008","unstructured":"Fatemi N, Dusick JR, Mattozo C, McArthur DL, Cohan P, Boscardin J, Wang C, Swerdloff RS, Kelly DF: Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery. 2008, 63: 709-718. 10.1227\/01.NEU.0000325725.77132.90.","journal-title":"Neurosurgery"},{"key":"31_CR164","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1210\/jc.81.5.1711","volume":"81","author":"SL Feigenbaum","year":"1996","unstructured":"Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB: Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab. 1996, 81: 1711-1719. 10.1210\/jc.81.5.1711.","journal-title":"J Clin Endocrinol Metab"},{"key":"31_CR165","first-page":"128","volume":"44","author":"HZ Gokalp","year":"2000","unstructured":"Gokalp HZ, Deda H, Attar A, Ugur HC, Arasil E, Egemen N: The neurosurgical management of prolactinomas. J Neurosurg Sci. 2000, 44: 128-132.","journal-title":"J Neurosurg Sci"},{"key":"31_CR166","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/BF01456107","volume":"85","author":"B Guidetti","year":"1987","unstructured":"Guidetti B, Fraioli B, Cantore GP: Results of surgical management of 319 pituitary adenomas. Acta Neurochir. 1987, 85: 117-124. 10.1007\/BF01456107.","journal-title":"Acta Neurochir"},{"key":"31_CR167","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11102-005-5086-1","volume":"8","author":"DK Hamilton","year":"2005","unstructured":"Hamilton DK, Vance ML, Boulos PT, Laws ER: Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary. 2005, 8: 53-60. 10.1007\/s11102-005-5086-1.","journal-title":"Pituitary"},{"key":"31_CR168","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1530\/acta.0.1250259","volume":"125","author":"T Hirohata","year":"1991","unstructured":"Hirohata T, Uozumi T, Mukada K, Arita K, Kurisu K, Yano T, Takechi A, Onda J: Influence of pregnancy on the serum prolactin level following prolactinoma surgery. Acta Endocrinol (Copenh). 1991, 125: 259-267.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR169","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3171\/jns.1985.63.6.0823","volume":"63","author":"ER Laws","year":"1985","unstructured":"Laws ER, Fode NC, Redmond MJ: Transsphenoidal surgery following unsuccessful prior therapy. An assessment of benefits and risks in 158 patients. J Neurosurg. 1985, 63: 823-829. 10.3171\/jns.1985.63.6.0823.","journal-title":"J Neurosurg"},{"key":"31_CR170","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1227\/00006123-198905000-00013","volume":"24","author":"G Maira","year":"1989","unstructured":"Maira G, Anile C, De Marinis L, Barbarino A: Prolactin-secreting adenomas: Surgical results and long-term follow-up. Neurosurgery. 1989, 24: 736-743. 10.1227\/00006123-198905000-00013.","journal-title":"Neurosurgery"},{"key":"31_CR171","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0090-3019(95)00430-0","volume":"45","author":"F Massoud","year":"1996","unstructured":"Massoud F, Serri O, Hardy J, Somma M, Beauregard H: Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surg Neurol. 1996, 45: 341-346. 10.1016\/0090-3019(95)00430-0.","journal-title":"Surg Neurol"},{"key":"31_CR172","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1179\/016164101101199199","volume":"23","author":"H Nakagawa","year":"2001","unstructured":"Nakagawa H, Iwatsuki K, Yamada M, Hagiwara Y, Moriuchi S, Kadota T: Latent prolactinoma on MRI-selective venous sampling and trans-sphenoidal microsurgical treatment. Neurol Res. 2001, 23: 691-696. 10.1179\/016164101101199199.","journal-title":"Neurol Res"},{"key":"31_CR173","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jocn.2004.10.003","volume":"12","author":"P Pandey","year":"2005","unstructured":"Pandey P, Ojha BK, Mahapatra AK: Pediatric pituitary adenoma: A series of 42 patients. J Clin Neurosci. 2005, 12: 124-127. 10.1016\/j.jocn.2004.10.003.","journal-title":"J Clin Neurosci"},{"key":"31_CR174","first-page":"499","volume":"164","author":"X Qu","year":"2011","unstructured":"Qu X, Wang M, Wang GD, Han T, Mou CZ, Han LZ, Jiang M, Qu YM, Zhang MA, Pang Q, Xu GM: Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur. 2011, 164: 499-504.","journal-title":"Eur"},{"key":"31_CR175","first-page":"161","volume":"14","author":"SE Rawe","year":"1980","unstructured":"Rawe SE, Williamson HO, Levine JH, Phansey SA, Hungerford D, Adkins WY: Prolactinomas: surgical therapy, indications and results. Surg Neurol. 1980, 14: 161-167.","journal-title":"Surg Neurol"},{"key":"31_CR176","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/0090-3019(86)90133-3","volume":"26","author":"Y Saitoh","year":"1986","unstructured":"Saitoh Y, Mori S, Arita N, Nagatani M, Hayakawa T, Koizumi K, Tanizawa O, Uozumi T, Mogami H: Treatment of prolactinoma based on the results of transsphenoidal operations. Surg Neurol. 1986, 26: 338-344. 10.1016\/0090-3019(86)90133-3.","journal-title":"Surg Neurol"},{"key":"31_CR177","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.surneu.2007.05.057","volume":"68","author":"A Santoro","year":"2007","unstructured":"Santoro A, Minniti G, Ruggeri A, Esposito V, Jaffrain-Rea ML, Delfini R: Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results. Surg Neurol. 2007, 68: 513-518. 10.1016\/j.surneu.2007.05.057.","journal-title":"Surg Neurol"},{"key":"31_CR178","first-page":"9","volume":"35","author":"C Scamoni","year":"1991","unstructured":"Scamoni C, Balzarini C, Crivelli G, Dorizzi A: Treatment and long-term follow-up results of prolactin secreting pituitary adenomas. J Neurosurg Sci. 1991, 35: 9-16.","journal-title":"J Neurosurg Sci"},{"key":"31_CR179","first-page":"301","volume":"63","author":"CC Shen","year":"2000","unstructured":"Shen CC, Wang YC, Wei-Shan H, Chang CS, Sun MH: Endoscopic endonasal transsphenoidal surgery for pituitary tumors. Chinese Med J (Taipei). 2000, 63: 301-310.","journal-title":"Chinese Med J (Taipei)"},{"key":"31_CR180","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1046\/j.1365-2265.1996.738559.x","volume":"44","author":"SG Soule","year":"1996","unstructured":"Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M: The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.[see comment]. Clin Endocrinol. 1996, 44: 711-716. 10.1046\/j.1365-2265.1996.738559.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR181","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2265.1992.tb02900.x","volume":"36","author":"J Webster","year":"1992","unstructured":"Webster J, Page MD, Bevan JS, Richards SH, Douglas-Jones AG, Scanlon MF: Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests. Clin Endocrinol. 1992, 36: 35-44. 10.1111\/j.1365-2265.1992.tb02900.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR182","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00701-003-0134-y","volume":"145","author":"S Wolfsberger","year":"2003","unstructured":"Wolfsberger S, Czech T, Vierhapper H, Benavente R, Knosp E: Microprolactinomas in males treated by transsphenoidal surgery. Acta Neurochir. 2003, 145: 935-940. 10.1007\/s00701-003-0134-y. discussion 940-931","journal-title":"Acta Neurochir"},{"key":"31_CR183","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1179\/174313208X310287","volume":"30","author":"HW Zhang","year":"2008","unstructured":"Zhang HW, Sun W, Yang J, Yan CX, Yu CJ: Diagnosis and treatment of pituitary microadenoma: report of 80 cases. Neurol Res. 2008, 30: 587-593. 10.1179\/174313208X310287.","journal-title":"Neurol Res"},{"key":"31_CR184","first-page":"119","volume":"16","author":"ZAB Jamjoom","year":"1995","unstructured":"Jamjoom ZAB, Malabarey T, Jamjoom AHB, Sulimani R, Rahman NU, Sadiq S: Problems in the management of large prolactin-secreting pituitary adenomas. Saudi Med J. 1995, 16: 119-125.","journal-title":"Saudi Med J"},{"key":"31_CR185","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1507\/endocrj.45.529","volume":"45","author":"N Saeki","year":"1998","unstructured":"Saeki N, Nakamura M, Sunami K, Yamaura A: Surgical indication after bromocriptine therapy on giant prolactinomas: Effects and limitations of the medical treatment. Endocr J. 1998, 45: 529-537. 10.1507\/endocrj.45.529.","journal-title":"Endocr J"},{"key":"31_CR186","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1210\/en.143.6.2093","volume":"143","author":"CJ Thompson","year":"2002","unstructured":"Thompson CJ, Tam NNC, Joyce JM, Leav I, Ho SM: Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in noble rats and response to the antiestrogen ICI 182,780. Endocrinology. 2002, 143: 2093-2105. 10.1210\/en.143.6.2093.","journal-title":"Endocrinology"},{"key":"31_CR187","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/bmj.309.6966.1409","volume":"309","author":"JA Thomson","year":"1994","unstructured":"Thomson JA, Davies DL, McLaren EH, Teasdale GM: Ten year follow up of microprolactinoma treated by transsphenoidal surgery. Br Med J. 1994, 309: 1409-1410. 10.1136\/bmj.309.6966.1409.","journal-title":"Br Med J"},{"key":"31_CR188","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0090-3019(00)00171-3","volume":"53","author":"HH Oruckaptan","year":"2000","unstructured":"Oruckaptan HH, Senmevsim O, Ozcan OE, Ozgen T: Pituitary adenomas: results of 684 surgically treated patients and review of the literature. Surg Neurol. 2000, 53: 211-219. 10.1016\/S0090-3019(00)00171-3.","journal-title":"Surg Neurol"},{"key":"31_CR189","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S0360-3016(96)00586-X","volume":"37","author":"S Rush","year":"1997","unstructured":"Rush S, Cooper PR: Symptom resolution, tumor control, and side effects following postoperative radiotherapy for pituitary macroadenomas. Int J Radiat Oncol Biol Phys. 1997, 37: 1031-1034. 10.1016\/S0360-3016(96)00586-X.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"31_CR190","first-page":"306","volume":"3","author":"SZ Badawy","year":"1997","unstructured":"Badawy SZ, Marziale JC, Rosenbaum AE, Chang JK, Joy SE: The long-term effects of pregnancy and bromocriptine treatment on prolactinomas\u2013the value of radiologic studies. Early Pregnancy. 1997, 3: 306-311.","journal-title":"Early Pregnancy"},{"key":"31_CR191","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2265.2007.02897.x","volume":"67","author":"K Berinder","year":"2007","unstructured":"Berinder K, Hulting AL, Granath F, Hirschberg AL, Akre O: Parity, pregnancy and neonatal outcomes in women treated for hyperprolactinaemia compared with a control group. Clin Endocrinol. 2007, 67: 393-397. 10.1111\/j.1365-2265.2007.02897.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR192","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1365-2265.2007.03000.x","volume":"68","author":"A Colao","year":"2008","unstructured":"Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL: Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol. 2008, 68: 66-71. 10.1111\/j.1365-2265.2007.03000.x.","journal-title":"Clin Endocrinol"},{"key":"31_CR193","first-page":"48","volume":"1","author":"P Cristiani","year":"1985","unstructured":"Cristiani P, De March A, Bulletti C: Follow-up of 17 hyperprolactinemic pregnant women by plasma prolactin levels and pituitary politomograms. J Gynaecol Endocrinol. 1985, 1: 48-51.","journal-title":"J Gynaecol Endocrinol"},{"key":"31_CR194","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/oxfordjournals.humrep.a137010","volume":"4","author":"PG Crosignani","year":"1989","unstructured":"Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P: Is pregnancy the best treatment for hyperprolactinaemia?. Hum Reprod. 1989, 4: 910-912.","journal-title":"Hum Reprod"},{"key":"31_CR195","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0028-2243(92)90094-F","volume":"44","author":"PG Crosignani","year":"1992","unstructured":"Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G: Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol. 1992, 44: 175-180. 10.1016\/0028-2243(92)90094-F.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"31_CR196","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0015-0282(16)60569-1","volume":"51","author":"G Godo","year":"1989","unstructured":"Godo G, Koloszar S, Szilagyi I, Daru J, Sas M: Experience relating to pregnancy, lactation, and the afterweaning condition of hyperprolactinemic patients treated with bromocriptine. Fertil Steril. 1989, 51: 529-531.","journal-title":"Fertil Steril"},{"key":"31_CR197","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1530\/acta.0.1110452","volume":"111","author":"U Holmgren","year":"1986","unstructured":"Holmgren U, Bergstrand G, Hagenfeldt K, Werner S: Women with prolactinoma\u2013effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol (Copenh). 1986, 111: 452-459.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"31_CR198","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","volume":"45","author":"WJ Jeffcoate","year":"1996","unstructured":"Jeffcoate WJ, Pound N, Sturrock ND, Lambourne J: Long-term follow-up of patients with hyperprolactinaemia. [see comment]. Clin Endocrinol (Oxf). 1996, 45: 299-303. 10.1046\/j.1365-2265.1996.00824.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"31_CR199","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","volume":"54","author":"S Karunakaran","year":"2001","unstructured":"Karunakaran S, Page RC, Wass JA: The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 2001, 54: 295-300. 10.1046\/j.1365-2265.2001.01190.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"31_CR200","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1471-0528.1979.tb11269.x","volume":"86","author":"WF Kelly","year":"1979","unstructured":"Kelly WF, Doyle FH, Mashiter K, Banks LM, Gordon H, Joplin GF: Pregnancies in women with hyperprolactinaemia: clinical course and obstetric complications of 41 pregnancies in 27 women. Br J Obstet Gynaecol. 1979, 86: 698-705. 10.1111\/j.1471-0528.1979.tb11269.x.","journal-title":"Br J Obstet Gynaecol"},{"key":"31_CR201","doi-asserted-by":"publisher","first-page":"473","DOI":"10.7326\/0003-4819-121-7-199410010-00001","volume":"121","author":"MJ Kupersmith","year":"1994","unstructured":"Kupersmith MJ, Rosenberg C, Kleinberg D: Visual loss in pregnant women with pituitary adenomas.[see comment]. Ann Intern Med. 1994, 121: 473-477.","journal-title":"Ann Intern Med"},{"key":"31_CR202","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0015-0282(16)48673-5","volume":"44","author":"C Rasmussen","year":"1985","unstructured":"Rasmussen C, Bergh T, Nillius SJ, Wide L: Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy. Fertil Steril. 1985, 44: 31-34.","journal-title":"Fertil Steril"},{"key":"31_CR203","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0301-2115(95)02257-0","volume":"63","author":"AM Rossi","year":"1995","unstructured":"Rossi AM, Vilska S, Heinonen PK: Outcome of pregnancies in women with treated or untreated hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol. 1995, 63: 143-146. 10.1016\/0301-2115(95)02257-0.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"31_CR204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000180019","volume":"21","author":"NJ Woodhouse","year":"1985","unstructured":"Woodhouse NJ, Niles N, McDonald D, McCorkell S: Prolactin levels in pregnancy: comparison of normal subjects with patients having micro- or macroadenomas after early bromocriptine withdrawal. Horm Res. 1985, 21: 1-9. 10.1159\/000180019.","journal-title":"Horm Res"},{"key":"31_CR205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1530\/acta.0.0920407","volume":"92","author":"A Zarate","year":"1979","unstructured":"Zarate A, Canales ES, Alger M, Forsbach G: The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol. 1979, 92: 407-412.","journal-title":"Acta Endocrinol"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2046-4053-1-33\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2046-4053-1-33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2046-4053-1-33","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2046-4053-1-33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T12:44:47Z","timestamp":1561985087000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/2046-4053-1-33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,24]]},"references-count":205,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1186\/2046-4053-1-33","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,24]]},"article-number":"33"}}